Kraemer, Markus http://orcid.org/0000-0002-5667-3621
Schwitalla, Jan Claudius
Diesner, Frank
Aktas, Orhan
Hartung, Hans-Peter
Berlit, Peter
Article History
Received: 26 January 2019
Revised: 5 March 2019
Accepted: 7 March 2019
First Online: 13 March 2019
Compliance with ethical standards
:
: Markus Kraemer received research grants from Novartis and Merck Serono and travel/accommodation/meeting expenses or lecture honoraria from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Teva and Shire Germany. Jan Claudius Schwitalla has no conflict of interest. Frank Diesner has no conflict of interest. Hans-Peter Hartung received, with approval of the Rector of Heinrich-Heine-University and the CEO of University of Düsseldorf Hospital honoraria for consulting, serving on steering committees and speaking from Biogen, CSL Behring, Geneuro, Genzyme, LFB, Medimmune, Merck, Novartis, Octapharma, Opexa, Receptos/Celgene, Roche, Sanofi, and Teva. Orhan Aktas received, with approval of the Rector of Heinrich-Heine-University, grants from the German Research Foundation (DFG), the German Ministry for Education and Research (BMBF) as part of the German Competence Network Multiple Sclerosis (KKNMS; for NEMOS NationNMO-PAT FKZ 01GI1602B), the Eugène Devic European Network (EU-FP7), honoraria and travel/accommodation/meeting expenses from Almirall, Bayer, Biogen, Medimmune, Merck Serono, Novartis, Roche, Sanofi-Genzyme, and Teva. Peter Berlit has no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.